Here's why the Orthocell (ASX:OCC) share price is on the move today

The company has taken another step in getting one of its star products internationally patented.

| More on:
medical doctor performing surgery using surgical instruments

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Orthocell Ltd (ASX: OCC) share price is climbing today. At the time of writing, it's at 57.5 cents, up by 1.77%, settling back after jumping 4% in early trading.

Let's have a look at the latest announcement from the regenerative medicine company.

What announcement did Orthocell make?

The Orthocell share price is moving higher after the company announced China and New Zealand have granted patents for its CelGro collagen medical device platform.

Australia and Japan have already granted patents for CelGro. Orthocell also said its patent applications were progressing in the United States and the European Union.

CelGro is a suture-less repair process used to regenerate soft tissue, meaning no potentially damaging stitches are needed. According to the statement, the process can improve the outcomes of surgeries by reducing surgery time, simplifying the techniques, and lessening the risk of additional trauma caused by stitches.

Orthocell reported preclinical studies indicate CelGro provides improved nerve repair and return of muscle function in patients with severed peripheral nerves compared to using sutures.

Orthocell's managing director, Paul Anderson, commented on the new patents:

These patents are an important addition to our global intellectual property portfolio, further strengthening our position in regenerative medicine product development and novel surgical techniques for soft tissue repair.

Sutureless or tensionless repair is of particular importance in the optimal repair of damaged nerves and is a key part of the repair process undertaken in the CelGro nerve regeneration clinical study. This comes at a perfect time for the company as we move our exciting pipeline products in nerve, tendon and ligament repair through the registration process in the US, EU and AUS.

The CelGro patents are set to expire on 12 October 2035.

Orthocell share price snapshot

Orthocell is currently trading at 57.5 cents per share. That puts Orthocell shares up by 64% over the past 12 months, well surpassing the 27% gains posted by the All Ordinaries Index (ASX: XAO).

Year-to-date, the Orthocell share price has continued to outperform, up 26% so far in 2021.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

This bombshell for ASX healthcare shares could hit 6 million Australians

This could have a large impact.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

2 ASX healthcare shares having a stellar run today

The ASX healthcare sector is down today but these two stocks are bucking the trend.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Why this $13 billion ASX 200 healthcare stock is surging today

A change in sentiment for the healthcare player.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX 200 stock hit a 52-week low and a top broker thinks it can rebound

Patient investors may see this stock make a pleasing recovery.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Why this sold-off ASX healthcare share could be an exciting dividend buy

This could be a healthy stock for dividends.

Read more »

a smiling woman sits at her computer at home with a coffee alongside her, as if pleased with her investments.
Healthcare Shares

Is CSL the best ASX 100 share to buy now?

Bell Potter has good things to say about this blue chip star.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
Healthcare Shares

Down 10% in a month, are CSL shares feeling the sting of a potential disruption?

Brokers are still bullish.

Read more »

One girl leapfrogs over her friend's back.
Healthcare Shares

Doubled in a year! Does this booming ASX share have another 24% upside?

Let's take a look.

Read more »